KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Deferred Taxes (2016 - 2017)

Travere Therapeutics (TVTX) has disclosed Deferred Taxes for 4 consecutive years, with $1.4 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Deferred Taxes rose 111.88% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2018, up 107.12%, and an annual FY2017 reading of -$6.4 million, up 71.65% over the prior year.
  • Deferred Taxes was $1.4 million for Q4 2017 at Travere Therapeutics, up from -$2.4 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $28.2 million in Q3 2015 and bottomed at -$40.0 million in Q1 2015.
  • Average Deferred Taxes over 4 years is -$3.9 million, with a median of -$2.9 million recorded in 2014.
  • Peak annual rise in Deferred Taxes hit 111.88% in 2017, while the deepest fall reached 285.78% in 2017.
  • Year by year, Deferred Taxes stood at -$2.5 million in 2014, then tumbled by 53.74% to -$3.8 million in 2015, then tumbled by 208.36% to -$11.7 million in 2016, then surged by 111.88% to $1.4 million in 2017.
  • Business Quant data shows Deferred Taxes for TVTX at $1.4 million in Q4 2017, -$2.4 million in Q3 2017, and -$3.4 million in Q2 2017.